87427-61-0

Basic information

• Product Name: 2-BroMo-1-(3,4-dichlorophenyl)propan-1-one
• Synonyms: 2-BroMo-1-(3,4-dichlorophenyl)propan-1-one
• CAS NO: 87427-61-0
• Molecular Formula: C₉H₇BrCl₂O
• Molecular Weight: 281.96128
• Mol File: 87427-61-0.mol
• Article Data: 12

Chemical Properties

• Appearance: /
• Solubility: DCM, Methanol
• CAS DataBase Reference: 2-BroMo-1-(3,4-dichlorophenyl)propan-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BroMo-1-(3,4-dichlorophenyl)propan-1-one(87427-61-0)
• EPA Substance Registry System: 2-BroMo-1-(3,4-dichlorophenyl)propan-1-one(87427-61-0)

Safety Data

• Hazardous Substances Data: 87427-61-0(Hazardous Substances Data)

Usage

Description

2-Bromo-1-(3,4-dichlorophenyl)propan-1-one is an organic compound that serves as a key intermediate in the synthesis of various chemical compounds. It is characterized by the presence of a bromine atom and two chlorine atoms attached to a phenyl ring, which is connected to a propanone group. This unique structure endows it with specific chemical properties that make it valuable in the development of pharmaceuticals and other chemical products.

Uses

Used in Pharmaceutical Industry:
2-Bromo-1-(3,4-dichlorophenyl)propan-1-one is used as a synthetic intermediate for the production of analogues of Bupropion (B689625). Bupropion is a well-known antidepressant and smoking cessation aid, and its analogues may exhibit similar or improved therapeutic effects. The synthesis of these analogues involves the use of 2-Bromo-1-(3,4-dichlorophenyl)propan-1-one as a crucial building block, allowing for the creation of new compounds with potential applications in the treatment of various medical conditions.

Upstream product

• 95-50-1 1,2-dichloro-benzene 
• 6582-42-9 1-(3,4-dichlorophenyl)propan-1-one 
• 7148-74-5 2-Bromopropionyl chloride 

Downstream Products

• 765278-99-7 2-phenyl-4-(3,4-dichlorophenyl)-5-methylimidazole 
• 1394204-83-1 2-(4-benzyl-5,6-dihydropyridin-1(2H)-yl)-1-(3,4-dichlorophenyl)propan-1-one 
• 1350716-78-7 2-(3,4-dichlorophenyl)-3,5,5-trimethylmorpholin-2-ol 

Relevant articles and documents

Discovery of the Oxadiazine FRM-024: A Potent CNS-Penetrant Gamma Secretase Modulator

The recent approval of aducanumab for Alzheimer's disease has heightened the interest in therapies targeting the amyloid hypothesis. Our research has focused on identification of novel compounds to improve amyloid processing by modulating gamma secretase activity, thereby addressing a significant biological deficit known to plague the familial form of the disease. Herein, we describe the design, synthesis, and optimization of new gamma secretase modulators (GSMs) based on previously reported oxadiazine 1. Potency improvements with a focus on predicted and measured properties afforded high-quality compounds further differentiated via robust Aβ42 reductions in both rodents and nonhuman primates. Extensive preclinical profiling, efficacy studies, and safety studies resulted in the nomination of FRM-024, (+)-cis-5-(4-chlorophenyl)-6-cyclopropyl-3-(6-methoxy-5-(4-methyl-1H-imidazole-1-yl)pyridin-2-yl)-5,6-dihydro-4H-1,2,4-oxadiazine, as a GSM preclinical candidate for familial Alzheimer's disease.

Hybrid dopamine uptake blocker-serotonin releaser ligands: A new twist on transporter-focused therapeutics

As part of our program to study neurotransmitter releasers, we report herein a class of hybrid dopamine reuptake inhibitors that display serotonin releasing activity. Hybrid compounds are interesting since they increase the design potential of transporter related compounds and hence represent a novel and unexplored strategy for therapeutic drug discovery. A series of N-alkylpropiophenones was synthesized and assessed for uptake inhibition and release activity using rat brain synaptosomes. Substitution on the aromatic ring yielded compounds that maintained hybrid activity, with the two disubstituted analogues (PAL-787 and PAL-820) having the most potent hybrid activity.

Novel Imidazole Derivatives Useful for the Treatment of Arthritis

The present invention provides compounds of the formula below: where A, X and R1-R6 are as described herein, a pharmaceutical salt thereof, and a pharmaceutical composition containing this compound; methods of treating pain associated with osteoarthritis using one of the compounds or a pharmaceutically acceptable salt thereof, and processes for preparing the compounds.